



Clinical Development of Drugs and Drug Combinations Modulating Immune Checkpoints in Cancer Therapy

Guest Editor:

Dr. Andrea Antonuzzo

Unit of Medical Oncology 1,
Azienda Ospedaliero-
Universitaria Pisana, Santa
Chiara Hospital, 56126 Pisa, Italy

Deadline for manuscript
submissions:

closed (30 September 2023)


Message from the Guest Editor

In recent years, the established role of immunotherapy as first-line treatment has improved prognosis for different cancers. Except for long-term responders, many patients may develop acquired resistance to immune checkpoint inhibitors (ICIs) causing relapses and progressive disease.

Immune checkpoint inhibitors (ICI) are a milestone in the treatment of many solid and hematological cancers despite a relevant part of patients do not have a clinical benefit and others develop primary resistance or progressive diseases.

Developing new combinations with other drugs is a real attempt to overcome this issue and, at the same time, warrant the need to maintain an adequate balance with the growth of immune related adverse events. The topic of toxicity should be the limit for many promising combination treatments and need to be further evaluated.





cancers

new combinations of ICIs with other drugs to enhance efficacy and activity in cancer care.

Research areas may include (but are not limited to) the following:

- New combination of ICIs;
- Clinical development of new drugs combination.

Indexed in:
PubMed

CITESCORE
8.0

IMPACT
FACTOR
4.5

an Open Access
Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)